In contrast, IL-6 antibodies failed in phase II clinical trials for IBD due to non-tolerable side effects (17, 18), including intestinal perforations which were also observed for anti-IL-6R therapy for rheumatoid arthritis (19). This evidence concerns the gene IL6R and inflammatory bowel disease.